Ann Lin amongst Forbes' 30 under 30

Ann Lin, who was a was a guest researcher at the Hybrid Technology Hub in 2018 and 2019, was recently listed as one of 30 under 30 in Forbes list for 2020 in the Science category.

Through the use of gene-editing technology, Lin and her teammates discovered that a successful cancer drug wasn't working because of what it was targeting, but because of a coincidental side effect. The impact of this research is leading to new procedures that can better confirm on-target activity of proposed cancer treatments.

Ann Lin is now a PhD. candidate at Standford University.

You read an interview of Ann from her time at the Hybrid Technology Hub

A paper from her stay in Oslo: 3D cell culture models and organ‐on‐a‐chip: Meet separation science and mass spectrometry

Published Dec. 4, 2019 2:51 PM - Last modified Aug. 13, 2020 12:39 PM